Good news comes in pairs for Metactive Medical of Olathe, Kan.

The company has been issued patents on two more devices it developed for the treatment of peripheral vascular and neurovascular diseases. It has also obtained $1.5 million in new financing.

The new patents are part of an intellectual property portfolio of numerous patent applications that Metactive has exclusive rights to in the U.S. and international markets. The portfolio covers four major patent families and includes methods of treating aneurysms, arteries and veins, as well as related embolization devices.

Metactive said the latest two patents are for its Ballstent Microcatherer, used for embolization of cerebral aneurysms, and its Blockstent Microcatherer, developed for embolization of peripheral arteries and veins.

“We designed the Blockstent and Ballstent devices to provide an ideal solution for embolization. These devices are low profile, easy to use, and can quickly be placed with a high degree of precision, resulting in immediate, complete and lasting cessation of blood flow,” said serial entrepreneur Dr. Nicholas Franano, president and CEO of Metactive.

The $1.5 million of additional Series A financing is co-led by Mid-America Angels, with the participation of a family office and additional individual investors. Metactive previously raised $7.5 million in Series A funding, bringing the total funding the company has raised to $9 million.

Franano is also the founder of Flow Forward Medical and Novita Therapeutics.